Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors

BACKGROUND: The utilization of modern-immunotherapies, notably immune checkpoint inhibitors (ICIs), has increased markedly in patients with metastatic melanoma over the past decade and are recommended as standard treatment. Given their increasing adoption in routine care for melanoma, understanding...

Descripción completa

Detalles Bibliográficos
Autores principales: Olateju, Olajumoke A., Zeng, Zhen, Thornton, J. Douglas, Mgbere, Osaro, Essien, Ekere James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339559/
https://www.ncbi.nlm.nih.gov/pubmed/37442992
http://dx.doi.org/10.1186/s12885-023-11142-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339559/
https://www.ncbi.nlm.nih.gov/pubmed/37442992
http://dx.doi.org/10.1186/s12885-023-11142-4

Ejemplares similares